Compare Stocks: KOD, PCVX, CYTK, and APGE

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
APGE Apogee Therapeutics	$135.07	$134.23	$35.39 ▼ $135.09	$8.40B	0.33	1.39 million shs	N/A
CYTK Cytokinetics	$72.72 -1.7%	$79.27	$47.22 ▼ $88.31	$9.05B	0.36	1.90 million shs	1.14 million shs
KOD Kodiak Sciences	$35.36 -2.8%	$40.33	$8.55 ▼ $47.84	$2.22B	2.18	569,729 shs	671,848 shs
PCVX Vaxcyte	$61.16 0.0%	$58.22	$30.81 ▼ $65.00	$9.10B	1.22	976,747 shs	986,686 shs

The 10 Best High-Yield Dividend Stocks for 2026

Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
APGE Apogee Therapeutics	-0.02%	+0.07%	+0.63%	+55.40%	+253.96%
CYTK Cytokinetics	-1.66%	+0.87%	-7.77%	+1.73%	+45.47%
KOD Kodiak Sciences	-2.75%	-6.26%	-18.92%	+13.88%	+312.60%
PCVX Vaxcyte	-0.02%	+2.22%	+9.37%	+29.14%	+90.53%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
APGE Apogee Therapeutics	$135.07	$134.23	$35.39 ▼ $135.09	$8.40B	0.33	1.39 million shs	N/A
CYTK Cytokinetics	$72.72 -1.7%	$79.27	$47.22 ▼ $88.31	$9.05B	0.36	1.90 million shs	1.14 million shs
KOD Kodiak Sciences	$35.36 -2.8%	$40.33	$8.55 ▼ $47.84	$2.22B	2.18	569,729 shs	671,848 shs
PCVX Vaxcyte	$61.16 0.0%	$58.22	$30.81 ▼ $65.00	$9.10B	1.22	976,747 shs	986,686 shs

The 10 Best High-Yield Dividend Stocks for 2026

Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
APGE Apogee Therapeutics	-0.02%	+0.07%	+0.63%	+55.40%	+253.96%
CYTK Cytokinetics	-1.66%	+0.87%	-7.77%	+1.73%	+45.47%
KOD Kodiak Sciences	-2.75%	-6.26%	-18.92%	+13.88%	+312.60%
PCVX Vaxcyte	-0.02%	+2.22%	+9.37%	+29.14%	+90.53%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
APGE Apogee Therapeutics	2.16	Hold	$126.77	-6.14% Downside
CYTK Cytokinetics	2.85	Moderate Buy	$103.37	42.15% Upside
KOD Kodiak Sciences	2.63	Moderate Buy	$48.14	36.15% Upside
PCVX Vaxcyte	2.50	Moderate Buy	$86.00	40.61% Upside

Current Analyst Ratings Breakdown

Latest KOD, PCVX, CYTK, and APGE Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/1/2026	CYTK Cytokinetics	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Overweight ➝ Buy
8/31/2026	CYTK Cytokinetics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$140.00
8/17/2026	KOD Kodiak Sciences	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$58.00
8/14/2026	CYTK Cytokinetics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
8/13/2026	APGE Apogee Therapeutics	Truist Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Hold	$81.00 ➝ $135.00
8/13/2026	CYTK Cytokinetics	Barclays Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$95.00 ➝ $110.00
8/13/2026	CYTK Cytokinetics	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$97.00 ➝ $103.00
8/12/2026	APGE Apogee Therapeutics	BTIG Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Buy ➝ Neutral
8/12/2026	PCVX Vaxcyte	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong Sell ➝ Hold
8/10/2026	CYTK Cytokinetics	Truist Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$106.00 ➝ $112.00
8/7/2026	CYTK Cytokinetics	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Outperform	$117.00 ➝ $112.00

(Data available from 9/5/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
APGE Apogee Therapeutics	N/A	N/A	N/A	N/A	$19.21 per share	N/A
CYTK Cytokinetics	$67.67M	133.72	N/A	N/A	($1.39) per share	-52.32
KOD Kodiak Sciences	N/A	N/A	N/A	N/A	$0.97 per share	N/A
PCVX Vaxcyte	N/A	N/A	N/A	N/A	$18.53 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
APGE Apogee Therapeutics	-$255.84M	-$4.34	N/A	N/A	N/A	N/A	-29.88%	-28.08%	11/9/2026 (Estimated)
CYTK Cytokinetics	-$784.96M	-$7.22	N/A	N/A	N/A	-1,321.12%	N/A	-51.01%	11/4/2026 (Estimated)
KOD Kodiak Sciences	-$229.97M	-$4.19	N/A	N/A	N/A	N/A	-273.23%	-85.48%	11/12/2026 (Estimated)
PCVX Vaxcyte	-$766.63M	-$7.63	N/A	N/A	N/A	N/A	-37.56%	-33.62%	11/3/2026 (Estimated)

Latest KOD, PCVX, CYTK, and APGE Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/12/2026	Q2 2026	KOD Kodiak Sciences	-$0.9565	-$1.05	-$0.0935	-$1.05	N/A	N/A
8/10/2026	Q2 2026	APGE Apogee Therapeutics	-$1.07	-$1.14	-$0.07	-$1.14	$10.00 million	N/A
8/6/2026	Q2 2026	CYTK Cytokinetics	-$1.63	-$1.50	+$0.13	-$1.50	$17.59 million	$28.62 million
8/5/2026	Q2 2026	PCVX Vaxcyte	-$2.06	-$1.97	+$0.09	-$1.97	$12.50 million	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
APGE Apogee Therapeutics	N/A	N/A	N/A	N/A	N/A
CYTK Cytokinetics	N/A	N/A	N/A	N/A	N/A
KOD Kodiak Sciences	N/A	N/A	N/A	N/A	N/A
PCVX Vaxcyte	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
APGE Apogee Therapeutics	N/A	26.44	26.44
CYTK Cytokinetics	N/A	6.66	6.66
KOD Kodiak Sciences	N/A	2.49	2.49
PCVX Vaxcyte	N/A	5.72	5.72

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
APGE Apogee Therapeutics	79.04%
CYTK Cytokinetics	N/A
KOD Kodiak Sciences	89.06%
PCVX Vaxcyte	96.78%

Insider Ownership

Company	Insider Ownership
APGE Apogee Therapeutics	24.30%
CYTK Cytokinetics	2.60%
KOD Kodiak Sciences	44.40%
PCVX Vaxcyte	3.30%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
APGE Apogee Therapeutics	91	62.20 million	47.09 million	Optionable
CYTK Cytokinetics	250	124.43 million	121.20 million	Optionable
KOD Kodiak Sciences	90	62.85 million	34.94 million	Optionable
PCVX Vaxcyte	160	148.81 million	143.89 million	Optionable

KOD, PCVX, CYTK, and APGE Headlines

Recent News About These Companies

Vaxcyte, Inc. $PCVX Stock Holdings Lowered by UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC

September 5 at 4:48 AM | marketbeat.com

Seven Fleet Capital Management LP Trims Holdings in Vaxcyte, Inc. $PCVX

September 5 at 4:40 AM | marketbeat.com

Vaxcyte Appoints Luis Jodar, David McAvoy To Leadership Team; Accelerates Phase 3 VAX-31 Timeline

September 4 at 12:58 PM | rttnews.com

Legal & General Group Plc Makes New Investment in Vaxcyte, Inc. $PCVX

September 4 at 4:39 AM | marketbeat.com

B. Metzler seel. Sohn & Co. AG Makes New Investment in Vaxcyte, Inc. $PCVX

September 4 at 3:12 AM | marketbeat.com

Vaxcyte Appoints Chief Medical Officer and Chief Legal Officer; Narrows Guidance for Expected VAX-31 OPUS-1 Topline Data

September 3 at 4:05 PM | globenewswire.com

Vaxcyte (NASDAQ:PCVX) COO Sells 3,477 Shares

September 3 at 6:37 AM | insidertrades.com

Corient Private Wealth LP Acquires New Holdings in Vaxcyte, Inc. $PCVX

September 3 at 3:44 AM | marketbeat.com

Jim Wassil Sells 3,477 Shares of Vaxcyte (NASDAQ:PCVX) Stock

September 2 at 9:07 PM | marketbeat.com

Alyeska Investment Group L.P. Cuts Holdings in Vaxcyte, Inc. $PCVX

September 1, 2026 | marketbeat.com

Man Group plc Acquires New Stake in Vaxcyte, Inc. $PCVX

August 31, 2026 | marketbeat.com

The Manufacturers Life Insurance Company Acquires Shares of 108,504 Vaxcyte, Inc. $PCVX

August 31, 2026 | marketbeat.com

Wellington Management Group LLP Has $407 Million Position in Vaxcyte, Inc. $PCVX

August 30, 2026 | marketbeat.com

502,135 Shares in Vaxcyte, Inc. $PCVX Purchased by Bank of New York Mellon Corp

August 30, 2026 | marketbeat.com

Vaxcyte, Inc. (NASDAQ:PCVX) Receives Average Recommendation of "Moderate Buy" from Analysts

August 29, 2026 | americanbankingnews.com

Vaxcyte, Inc. (NASDAQ:PCVX) Given Consensus Recommendation of "Moderate Buy" by Analysts

August 29, 2026 | marketbeat.com

Vaxcyte to Participate in Upcoming Investor Conferences

August 27, 2026 | globenewswire.com

Odyssean LLC Grows Stake in Vaxcyte, Inc. $PCVX

August 26, 2026 | marketbeat.com

Jupiter Topco LLC Purchases Shares of 17,965,847 Vaxcyte, Inc. $PCVX

August 26, 2026 | marketbeat.com

Elmind Capital LP Takes Position in Vaxcyte, Inc. $PCVX

August 26, 2026 | marketbeat.com

ADAR1 Capital Management LLC Makes New $8.49 Million Investment in Vaxcyte, Inc. $PCVX

August 26, 2026 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

KOD, PCVX, CYTK, and APGE Company Descriptions

Apogee Therapeutics NASDAQ:APGE

$135.07 0.00 (0.00%)

As of 09/4/2026

Apogee Therapeutics, Inc., through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), asthma, chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company primarily develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for AD; and APG808, an SQ extended half-life mAb for COPD. Its earlier-stage programs comprise APG990, an SQ extended half-life mAb for the treatment of AD; and APG222, an extended half-life SQ antibodies for AD. Apogee Therapeutics, Inc. was incorporated in 2022 and is headquartered in Waltham, Massachusetts.

Cytokinetics NASDAQ:CYTK

$72.72 -1.23 (-1.66%)

As of 09/4/2026 04:00 PM Eastern

Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is in Phase III clinical trial in patients with heart failure. The company also develops CK-136, a novel cardiac troponin activator that is in Phase I clinical trial; CK-586, a small molecule cardiac myosin inhibitor, that is in Phase I clinical trial; and aficamten, a novel cardiac myosin inhibitor, which is in Phase III clinical trial for the treatment of patients with symptomatic obstructive hypertrophic cardiomyopathy. Cytokinetics, Incorporated has a strategic alliance with Ji Xing Pharmaceuticals Limited. The company was incorporated in 1997 and is headquartered in South San Francisco, California.

Kodiak Sciences NASDAQ:KOD

$35.36 -1.00 (-2.75%)

As of 09/4/2026 04:00 PM Eastern

Kodiak Sciences Inc., a clinical stage biopharmaceutical company, researches, develops, and commercializes therapeutics to treat retinal diseases. Its lead product candidate is tarcocimab tedromer (KSI-301), an anti-vascular endothelial growth factor antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD), as well as Phase III clinical study for the treatment of diabetic macular edema, naïve macular edema due to retinal vein occlusion, and non-proliferative diabetic retinopathy. The company's preclinical stage product candidate includes KSI-501, a bispecific conjugate to treat retinal diseases with an inflammatory component; and KSI-601, a triplet biopolymer conjugate for the treatment of dry AMD. The company was formerly known as Oligasis, LLC and changed its name to Kodiak Sciences Inc. in September 2015. Kodiak Sciences Inc. was incorporated in 2009 and is based in Palo Alto, California.

Vaxcyte NASDAQ:PCVX

$61.16 -0.01 (-0.02%)

As of 09/4/2026 04:00 PM Eastern

Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness. The company was formerly known as SutroVax, Inc. and changed its name to Vaxcyte, Inc. in May 2020. Vaxcyte, Inc. was incorporated in 2013 and is headquartered in San Carlos, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest KOD, PCVX, CYTK, and APGE Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest KOD, PCVX, CYTK, and APGE Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

KOD, PCVX, CYTK, and APGE Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

KOD, PCVX, CYTK, and APGE Company Descriptions

Apogee Therapeutics NASDAQ:APGE

Cytokinetics NASDAQ:CYTK

Kodiak Sciences NASDAQ:KOD

Vaxcyte NASDAQ:PCVX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest KOD, PCVX, CYTK, and APGE Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest KOD, PCVX, CYTK, and APGE Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

KOD, PCVX, CYTK, and APGE Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

KOD, PCVX, CYTK, and APGE Company Descriptions

Apogee Therapeutics NASDAQ:APGE

Cytokinetics NASDAQ:CYTK

Kodiak Sciences NASDAQ:KOD

Vaxcyte NASDAQ:PCVX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools